NASDAQ:DARE

Daré Bioscience - DARE Stock Forecast, Price & News

$1.27

+0.03 (+2.41%)

(As of 01/31/2023 10:57 AM ET)

Add

Compare

Today's Range: $1.26
▼
$1.28
50-Day Range: $0.82
▼
$1.36
52-Week Range: $0.82
▼
$1.88

Volume: 87,351 shs
Average Volume: 485,148 shs
Market Capitalization: $108.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Institutional Ownership

Daré Bioscience MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 629.2% Upside
$9.33 Price Target
Short Interest: Healthy
1.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.13
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.32) to ($0.35) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

618th out of 1,055 stocks

Pharmaceutical Preparations Industry

311th out of 518 stocks

3.5

Analyst's Opinion

Consensus Rating
Daré Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.33, Daré Bioscience has a forecasted upside of 629.2% from its current price of $1.28.
Amount of Analyst Coverage
Daré Bioscience has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.39% of the outstanding shares of Daré Bioscience have been sold short.
Short Interest Ratio / Days to Cover
Daré Bioscience has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Daré Bioscience has recently decreased by 13.24%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Daré Bioscience does not currently pay a dividend.
Dividend Growth
Daré Bioscience does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DARE.

4.0

News and Social Media Coverage

News Sentiment
Daré Bioscience has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Daré Bioscience this week, compared to 1 article on an average week.
Search Interest
13 people have searched for DARE on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.
MarketBeat Follows
10 people have added Daré Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Daré Bioscience insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Daré Bioscience is held by insiders.
Percentage Held by Institutions
Only 9.19% of the stock of Daré Bioscience is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Daré Bioscience are expected to decrease in the coming year, from ($0.32) to ($0.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Daré Bioscience is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Daré Bioscience is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Daré Bioscience has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Daré Bioscience (NASDAQ:DARE) Stock

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Stock News Headlines

January 27, 2023 | msn.com

Dare County woman wins $150K on scratch ticket

January 26, 2023 | finance.yahoo.com

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

January 31, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 25, 2023 | msn.com

Daré Bioscience hits seven-month high after regaining listing compliance

January 21, 2023 | finance.yahoo.com

Daré Bioscience (NASDAQ:DARE) investors are sitting on a loss of 49% if they invested five years ago

January 10, 2023 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on Daré Bioscience (DARE)

January 10, 2023 | msn.com

Daré Bioscience Shares Move Higher Intravaginal Ring Shows Promise In Menopause Symptoms

January 9, 2023 | finance.yahoo.com

All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy

January 31, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 9, 2023 | finance.yahoo.com

Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

January 7, 2023 | forbes.com

Dare Bioscience

December 13, 2022 | msn.com

HC Wainwright & Co. Maintains Buy Rating for Dare Bioscience: Here's What You Need To Know

November 15, 2022 | finance.yahoo.com

Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

November 15, 2022 | finance.yahoo.com

Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health

November 14, 2022 | finance.yahoo.com

Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

November 11, 2022 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Daré Bioscience (DARE)

November 11, 2022 | seekingalpha.com

Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript

November 10, 2022 | finance.yahoo.com

Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update

November 10, 2022 | finance.yahoo.com

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

November 8, 2022 | finance.yahoo.com

Daré Bioscience to Present at the Stifel 2022 Healthcare Conference

November 3, 2022 | msn.com

Dare 2 Care helps fund Leeza’s Care Connection

November 3, 2022 | msn.com

‘Truth or Dare’ Director Alek Keshishian Says Madonna Asked for a Sequel, but ‘We Just Didn’t See Eye to Eye’

November 3, 2022 | finance.yahoo.com

Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022

November 1, 2022 | finance.yahoo.com

Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

October 25, 2022 | benzinga.com

Can This Company's Birth Control Patch Disrupt The Contraceptive Market?

October 19, 2022 | msn.com

Fair Oaks man accused of murder in fentanyl death of Auburn woman

October 17, 2022 | finance.yahoo.com

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Company Calendar

Last Earnings: 11/10/2022
Today: 1/31/2023
Next Earnings (Estimated): 3/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DARE
CUSIP: N/A
CIK: 1401914
Web: www.darebioscience.com
Phone: (858) 926-7655
Fax: 617-494-1544
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.33
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +331.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,700,000.00
Net Margins: N/A
Pretax Margin: -245.47%
Return on Equity: -76.11%
Return on Assets: -47.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.17
Quick Ratio: 2.17

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.51 per share
Price / Book: 2.50

Miscellaneous

Outstanding Shares: 84,820,000
Free Float: 81,432,000
Market Cap: $108.15 million
Optionable: Not Optionable
Beta: 1.17

Key Executives

Sabrina Martucci Johnson
President, CEO, Secretary & Director

Mark Walters
Vice President-Operations

Lisa Walters-Hoffert
Chief Financial Officer

Christine Mauck
Medical Director

David Friend
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

DARE Stock - Frequently Asked Questions

Should I buy or sell Daré Bioscience stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DARE shares.
View DARE analyst ratings or view top-rated stocks.
What is Daré Bioscience's stock price forecast for 2023?: 4 analysts have issued 12 month price objectives for Daré Bioscience's stock. Their DARE share price forecasts range from $4.00 to $17.00. On average, they anticipate the company's share price to reach $9.33 in the next year. This suggests a possible upside of 649.7% from the stock's current price.
View analysts price targets for DARE or view top-rated stocks among Wall Street analysts.
How have DARE shares performed in 2023?: Daré Bioscience's stock was trading at $0.83 at the beginning of 2023. Since then, DARE shares have increased by 50.0% and is now trading at $1.2450.
View the best growth stocks for 2023 here.
Are investors shorting Daré Bioscience?: Daré Bioscience saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 1,180,000 shares, a decline of 13.2% from the December 31st total of 1,360,000 shares. Based on an average trading volume of 229,500 shares, the days-to-cover ratio is currently 5.1 days.
View Daré Bioscience's Short Interest.
When is Daré Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our DARE earnings forecast.
How were Daré Bioscience's earnings last quarter?: Daré Bioscience, Inc. (NASDAQ:DARE) posted its earnings results on Thursday, November, 10th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03.

What other stocks do shareholders of Daré Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).
What is Daré Bioscience's stock symbol?: Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."
Who are Daré Bioscience's major shareholders?: Daré Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Daré Bioscience?: Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Daré Bioscience's stock price today?: One share of DARE stock can currently be purchased for approximately $1.25.
How much money does Daré Bioscience make?: Daré Bioscience (NASDAQ:DARE) has a market capitalization of $105.61 million and generates $10 million in revenue each year. The biotechnology company earns $-38,700,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.
How can I contact Daré Bioscience?: Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The official website for the company is www.darebioscience.com. The biotechnology company can be reached via phone at (858) 926-7655, via email at innovations@darebioscience.com, or via fax at 617-494-1544.

This page (NASDAQ:DARE) was last updated on 1/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Daré Bioscience - DARE Stock Forecast, Price & News

Daré Bioscience MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Daré Bioscience (NASDAQ:DARE) Stock

DARE Stock News Headlines

DARE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DARE Stock - Frequently Asked Questions

Overall MarketRank^™